Urotensin II in Chronic Kidney Diseases and Kidney Transplants

The investigators are planning to study the serum level of Urotensin II in chronic kidney disease patients, kidney transplants, and healthy controls.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Renal Disease Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Vakif Gureba Training & Research Hospital

Istanbul, 34100, Turkey (Türkiye)

About this study

The investigators will determine the urotensin II levels in Chronic kidney disease patients, kidney transplants, and healthy controls.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age more than 18

Exclusion criteria

Inability to give a written consent

Treatment and study plan

Primary outcomes

serum Urotensin II(UII)level

Time frame: at enrollment

We tried to compare UII level in normal, chronic kidney disease and kidney transplant patients group

Sponsors and collaborators

Lead sponsor

Vakif Gureba Training and Research Hospital

Other

Registry information

Official study title

Urotensin II in Chronic Kidney Diseases

Important dates

Study start: 2010
Primary completion: 2010
Study completion: 2010
First posted: Apr 5, 2010
Registry last updated: Jun 13, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed